Clinical Pfizer signs agreement to acquire Trillium Therapeutics for $2.26B

Pfizer signs agreement to acquire Trillium Therapeutics for $2.26B


Pfizer is all set to acquire a clinical-stage immuno-oncology company, Trillium Therapeutics Inc., with all its outstanding shares, for $2.26 billion (or $18.5 per share) in liquid form.

The closing of the acquisition is expected after regulatory’s approval and fulfilment of some necessary closing conditions.

Trillium is working on developing state-of-the-art therapies for cancers and biologics that could help boost the natural immune system to identify and destroy cancer cells.

The Canada based biotech has two lead molecules TTI-621 and TTI-622 that hampers the signal-regulatory protein α (SIRPα)–CD47 axis, which is a main immune checkpoint inhibitor, a leading cause in haematological cancers.

The two above mentioned proteins are SIRPα-Fc fusion proteins which are in phase Ib/II development stage targeting haematological malignancies in particular.   

Pfizer intends to accelerate the clinical development of the SIRPα fusion proteins and examine different combinations within the company’s portfolio and with new therapies for haematological malignancies. Their addition to the company will further strengthen US pharma giant’s oncology pipeline.

These immuno-therapeutics became active as a monotherapy in clinical studies for refractory or relapsed lymphoid malignancies including diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), follicular lymphoma (FL) and more.

Andy Schmeltz, Pfizer Oncology Global President and General Manager, said, “The proposed acquisition of Trillium builds on our strong track record of leadership in Oncology, enhancing our haematology portfolio as we strive to improve outcomes for people living with blood cancers around the globe.”

Pfizer’s acquisition decision followed a $25 million investment in Trillium Therapeutics, which it made by means of Pfizer Breakthrough Growth Initiative (PBGI), in September last year.

As a consequence, Trillium’s Senior Vice President and Chief Scientific Officer of Oncology R&D Group, Jeff Settleman joined Pfizer’s scientific advisory board.    

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you